Oncternal Therapeutics, Inc.: Nasdaq/NYSE listing notice — Oncternal receives Nasdaq deficiency notice for bid price below $1.00

Oncternal Therapeutics, Inc.

Received Nasdaq deficiency letter on April 4, 2023 due to closing bid price below $1.00 for 30 consecutive business days.
Has until October 2, 2023 to regain compliance by closing at $1.00 or more for at least 10 consecutive trading days.
May consider a reverse stock split if approved by stockholders to cure the bid-price deficiency.
Stock continues trading on Nasdaq Capital Market under ONCT; no immediate delisting impact.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Oncternal Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

April 4, 2023, Oncternal Therapeutics, Inc. (“Oncternal”) received a letter from the Nasdaq staff indicating that, for the last thirty consecutive business days, the bid price for Oncternal’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), Oncternal has been provided an initial period of 180 calendar days, or until October 2, 2023, to regain compliance. The letter states that the Nasdaq staff will provide written notification that

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0000950170-23-012103

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.